Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextromethorphan Dosing in Major Depressive Disorder
NCT04226352Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dextromethorphan in major depressive disorder (MDD) (3 arms), sponsored by Johns Hopkins University. Primary endpoint: Time to All-Cause Discontinuation of Dextromethorphan at 90 days. Started Mar 2020; status: completed.
02
Drugs
dextromethorphan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04226352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226352.